Results 31 to 40 of about 602,416 (352)

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Scientific Reports, 2021
A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies.
M. Poblocka, A. Bassey, V. Smith, M. Falcicchio, A. S. Manso, M. Althubiti, Xiaobo Sheng, A. Kyle, R. Barber, M. Frigerio, S. Macip   +10 more
semanticscholar   +1 more source

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Frontiers in Pharmacology, 2021
The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation methods.
Dian Su, Donglu Zhang
semanticscholar   +1 more source

ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Blood, 2021
Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL), typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is often fatal. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is
T. Vaisitti, F. Arruga, Nicoletta Vitale, Th Lee, Mira Ko, A. Chadburn, E. Braggio, A. Di Napoli, Andrea Iannello, J. Allan, L. Miller, B. Lannutti, R. Furman, Katti A. Jessen, S. Deaglio   +14 more
semanticscholar   +1 more source

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]

, 2016
First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa, Das, Swadesh K, De, Surya K, Emdad, Luni, Fisher, Paul B, Morvaridi, Susan Kharagh, Pandol, Stephen J, Pellecchia, Maurizio, Quinn, Bridget A, Sarkar, Devanand, Stebbins, John L, Wang, Si   +11 more
core   +5 more sources

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

Neuro-Oncology, 2021
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a ...
B. Marin, K. Porath, Sonia Jain, Minjee Kim, Jason E. Conage-Pough, Ju-Hee Oh, Caitlyn L. Miller, Surabhi Talele, G. Kitange, Shulan Tian, Danielle M. Burgenske, A. Mladek, Shiv K. Gupta, P. Decker, M. McMinn, S. Stopka, M. Regan, Lihong He, B. Carlson, K. Bakken, T. Burns, I. Parney, C. Giannini, N. Agar, J. Eckel-Passow, J. Cochran, W. Elmquist, R. Vaubel, F. White, J. Sarkaria   +29 more
semanticscholar   +1 more source

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]

, 2019
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen   +6 more
core   +1 more source

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Antibodies, 2019
Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey, Asa Frostell, Tim Fagge, Deyarina Gonzalez, R. Steven Conlan   +4 more
doaj   +1 more source

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source

Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors.

Antibody Therapeutics, 2021
Background ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers.
Hu Li, Xiao Zhang, Zhenyi Xu, Lingrui Li, Wenchao Liu, Zhenyu Dai, Zhongrun Zhao, Lili Xiao, Hongfeng Li, Chaohong Hu   +9 more
semanticscholar   +1 more source

Antibody drug conjugates

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +1 more source